Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
about
Myocardial strain imaging: how useful is it in clinical decision making?Cardiac toxicity in cancer survivorsThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaNeuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclinesTargeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of CardiologyUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Twenty years of anti-HER2 therapy-associated cardiotoxicityRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Nuclear imaging in detection and monitoring of cardiotoxicity.Concomitant low-dose doxorubicin treatment and exerciseStem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Ageing is a risk factor in imatinib mesylate cardiotoxicityCardiovascular disease after cancer therapy.CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes.Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.Targeted therapies in breast cancer: are heart and vessels also being targeted?Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Primary proteasome inhibition results in cardiac dysfunctionAsymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance.Cardiac side effects of anticancer treatments: new mechanistic insightsLow to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for 'late effects' screening and preventive strategies.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.Cardiovascular disease in survivors of hematopoietic cell transplantation.Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
P2860
Q26778343-58DF50A4-0201-4B6A-8984-E28E088C75FEQ26851957-B34A3C00-B4DA-4C7D-BD35-7D86E90E1AC9Q27011540-54498699-3850-4AFC-AC66-AB701480DD96Q27013665-8EBF785A-A93C-4004-9749-3AF571E9221EQ27022965-E5EF1AA1-3CB5-4E27-A99E-2AE5545A3F80Q27024879-3542A6F7-BAA9-4972-9046-DAB316780E7CQ27027354-A3FCEB9A-B1F4-49A4-8BD2-83A6A2ABEAC9Q28079391-14F697BC-A2D1-496B-BAF5-1D349D1997F9Q28087776-0FBDB0AA-6B91-4947-BE60-72CBBA8AE0D7Q28545130-6458CECC-64D4-498A-AB03-17231699F6DAQ30401812-712ABC54-00C8-43F0-91D9-AFA4FFD6567CQ30426853-A8528D38-67F2-4FEC-8972-32A53D4D0E42Q33807542-639B2808-FBF6-4013-BE54-2B5FD4939BD2Q33942611-F604EFB4-A23E-480D-897F-69F7466CF725Q34201221-7653E029-19B3-4F2C-A00C-CF36021D4CB9Q34441749-F7F48019-D2CA-4409-84A5-B1726B9D4576Q34548719-7B847302-6451-4B3D-B5D1-312208D00AADQ34604429-12B30289-F02C-4E69-9DA5-5E5B37FB0525Q35580896-3369DF91-E153-497C-AAC1-89715D3A13CEQ35673776-995AB576-1DC5-4A5B-BB42-138928A6DFBCQ35905883-1014AECB-3D02-49FC-8B5B-47DD0ABC3D87Q35997676-365FA8E1-2595-4D43-A255-4342FF4B5B3DQ36092046-212A42F7-6C9C-4A31-83E1-1EA1A6B46429Q36168700-2B45C0CF-FE45-43FD-9CB4-8B95EBBD6BBEQ36212048-9BD45E69-A317-429F-B62D-12BB3C918920Q36245324-9F45369D-B476-4862-89A1-57D7C8232B42Q36339976-3033D89C-E1CB-4F84-9BAF-323843CF1686Q36551901-316B4A66-FC3C-425E-9996-0C708A65476EQ36865776-24C35DAC-8B69-402A-8E7F-7B802657996DQ36939536-895AB81E-5784-4448-A123-BF525BE1B1B5Q36957758-156A2C52-A7C4-4A44-9058-B62839DDD923Q37100862-B817B4AD-7050-4D1F-B3E9-71A030201BD2Q37107428-7F3B057D-8AA6-4F3C-9306-67A857A8753EQ37131070-444E4C12-7637-467D-A29F-C19F98F7477CQ37311943-C29E64D8-76DF-4AFD-8A60-5CCC69B4B9BFQ37325674-C915E2FC-5F24-477F-A6D4-D095ED5DE05AQ37397983-F0A8760F-B086-4B1C-B14D-FD438E511581Q37560059-D5F6F763-C1A7-4D91-8453-A6223DF92758Q37624268-76FEA9A3-1C1F-487E-A9E0-15FDF639B8CBQ37671456-4DADB5B0-846E-4C56-B820-1BF24DD87A82
P2860
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular side effects of ...... uropean Society of Cardiology.
@en
Cardiovascular side effects of ...... uropean Society of Cardiology.
@nl
type
label
Cardiovascular side effects of ...... uropean Society of Cardiology.
@en
Cardiovascular side effects of ...... uropean Society of Cardiology.
@nl
prefLabel
Cardiovascular side effects of ...... uropean Society of Cardiology.
@en
Cardiovascular side effects of ...... uropean Society of Cardiology.
@nl
P2093
P50
P356
P1476
Cardiovascular side effects of ...... uropean Society of Cardiology.
@en
P2093
Arne Hansen
Dirk L Brutsaert
Douglas Sawyer
Joseph A Hill
Mathias Rauchhaus
Michael S Ewer
Peter H Sugden
Stefan Janssens
Stephane Heymans
Steven de Jong
P356
10.1093/EURJHF/HFQ213
P50
P577
2011-01-01T00:00:00Z